bet88 slot

bet88 slot

Over 18,000 in Mexico register to run for Supreme Court seats and federal judges in new systemSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - CRBUSmall Funder? How to Get Fast Tracked With Big Investors

Washington Capitals star Alex Ovechkin has a broken left fibula and is expected to miss 4 to 6 weeks

Bus driver left ‘absolutely terrified’ after vehicle vandalised by group on pub tourTrump tariffs threaten to crack open North American economiesEmpowering youth & fostering innovation crucial for Viksit Bharat: Jitendra Singh‘Can’t park there buddy’: Yacht slams into bridge

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Zeta Global Holdings Corp. (NYSE: ZETA) securities between February 27, 2024 and November 13, 2024. Zeta is a marketing technology company. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Zeta Global Holdings Corp. (ZETA) Failed to Disclose it was Artificially Inflating Financial Results According to the complaint, on November 13, 2024, market research group Culper Research published a report entitled "Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam.” The report alleged that the “integrity of the Company’s data collection and reported financials” is severely undermined by two factors. First, the report alleged that “Zeta has formed ‘two-way’ contracts with third party consent farms wherein the Company simultaneously acts as both a supplier and a buyer of consumer data,” allowing the Company to “flatter reported revenue growth” and indicating possible “round-tripping” of revenue. Second, the report alleged that Zeta’s collects the majority of its customer data from a network of “sham websites that hoodwink millions of consumers each month into handing their data over to Zeta under false pretenses.” For example, the report alleged the Company and its subsidiaries operate a number of fake job boards which are designed to trick individuals into submitting personal data under the pretense of job applications. The report further alleged that the Company’s “most valuable data” comes from these predatory websites, dubbed consent farms, which are “responsible for almost the entirety of the Company’s growth.” On this news, the Company’s stock price fell $10.46, or 37.07%, to close at $17.76 per share on November 13, 2024. Plaintiff alleges that during the class period, defendants failed to disclose that: (1) Zeta used two-way contracts to artificially inflate financial results; (2) Zeta engaged in round trip transactions to artificially inflate financial results; (3) Zeta utilized predatory consent farms to collect user data; and (4) that these consent farms have driven almost the entirety of Zeta’s growth. What Now: You may be eligible to participate in the class action against Zeta Global Holdings Corp. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by January 21, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Zeta Global Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9e62a12-06db-424e-a9a1-12ca4ed447d5A Japanese sake maker is going where no sake maker has gone before: space. Asahi Shuzo, the company behind the popular Japanese sake brand Dassai, plans to blast sake ingredients to the International Space Station (ISS) to ferment a very special brew. Related video above: The dark energy pushing our universe apart may not be what it seems, scientists say If it works, just one 100ml bottle will be offered for sale on Earth at 100 million yen, or about $653,000. A standard serve is 80ml, making it one very expensive drink. “There is no guarantee of 100% success for the fermentation tests,” said Souya Uetsuki, the brewer in charge of the project at Asahi Shuzo. He said the difference in gravity could affect how heat transfers in fluid, causing a different fermentation process in space than on Earth. The company has paid the Japan Aerospace Exploration Agency for access to the Kibo experiment module, part of the ISS developed by Japan, where tests can be conducted in a “special microgravity environment.” The national space agency said they would not comment on the privately paid project. Sake is made of Japanese rice, water, yeast and koji (a type of mold). It traditionally takes about two months to make through a series of precise steps that involve steaming, stirring and fermenting. The drink is sipped from a glass at many Japanese cultural occasions — from weddings to meals at pub-like izakaya restaurants — and last week landed a spot on UNESCO’s list of the “intangible cultural heritage of humanity.” Dassai — meaning “otter festival” in Japanese — is one of the most popular sake brands on the market. However, its maker is also behind premium products that are popular with collectors, some willing to spend up to thousands of dollars for a bottle. Asahi Shuzo’s foray into space is more than just another attempt to make another rare sake, according to the brewer. Uetsuki said the company hoped the project would offer insights into how fermentation works in space, so perhaps one day they can make sake on the moon. “In a future where humans can freely travel between the moon and Earth, some will visit the moon as tourists. This project aims to create sake that can be enjoyed on the moon, allowing visitors to have delightful moments there,” he said. He hopes the technology will also benefit future space tourists who have a penchant for other types of fermented food. “Many Japanese foods, such as natto and miso, are fermented, and this technology could expand into these areas,” Uetsuki said. The company is developing space brewing equipment, with a planned launch date later in 2025.

Broncos hope to continue playoff push when they meet the banged-up RaidersCerity Partners LLC grew its stake in shares of DexCom, Inc. ( NASDAQ:DXCM – Free Report ) by 190.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,050 shares of the medical device company’s stock after purchasing an additional 39,344 shares during the period. Cerity Partners LLC’s holdings in DexCom were worth $4,026,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. raised its holdings in shares of DexCom by 132.0% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock worth $522,000 after acquiring an additional 2,143 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of DexCom by 76.4% during the first quarter. Cetera Investment Advisers now owns 106,881 shares of the medical device company’s stock valued at $14,824,000 after buying an additional 46,297 shares during the last quarter. Cetera Advisors LLC grew its holdings in DexCom by 593.4% during the first quarter. Cetera Advisors LLC now owns 40,808 shares of the medical device company’s stock worth $5,660,000 after buying an additional 34,923 shares in the last quarter. American Trust purchased a new stake in DexCom in the 1st quarter valued at $212,000. Finally, HM Payson & Co. lifted its stake in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 97.75% of the company’s stock. DexCom Stock Down 0.1 % DXCM stock opened at $77.99 on Friday. The stock has a 50-day simple moving average of $71.39 and a two-hundred day simple moving average of $88.11. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market capitalization of $30.46 billion, a PE ratio of 46.70, a PEG ratio of 2.39 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. Analysts Set New Price Targets Get Our Latest Stock Analysis on DexCom Insider Activity at DexCom In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last 90 days, insiders sold 5,431 shares of company stock valued at $399,319. Corporate insiders own 0.30% of the company’s stock. About DexCom ( Free Report ) DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. Featured Articles Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter .